Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ROSG
- CUSIP: N/A
- Web: www.rosettagenomics.com
- Market Cap: $4.21 million
- Outstanding Shares: 1,868,000
- 50 Day Moving Avg: $1.60
- 200 Day Moving Avg: $2.37
- 52 Week Range: $1.25 - $11.52
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.34
- P/E Growth: 0.00
- Annual Revenue: $9.23 million
- Price / Sales: 0.28
- Book Value: $2.40 per share
- Price / Book: 0.57
- EBIDTA: ($14,760,000.00)
- Net Margins: -175.92%
- Return on Equity: -155.54%
- Return on Assets: -108.98%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 2.50%
- Quick Ratio: 2.50%
- Average Volume: 90,700 shs.
- Beta: 0.77
- Short Ratio: 6.64
Frequently Asked Questions for Rosetta Genomics (NASDAQ:ROSG)
What is Rosetta Genomics' stock symbol?
Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG."
How were Rosetta Genomics' earnings last quarter?
Rosetta Genomics Ltd. (NASDAQ:ROSG) released its quarterly earnings data on Thursday, May, 19th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.02. The business earned $2.60 million during the quarter, compared to the consensus estimate of $3.36 million. Rosetta Genomics had a negative return on equity of 155.54% and a negative net margin of 175.92%. View Rosetta Genomics' Earnings History.
When will Rosetta Genomics make its next earnings announcement?
Where is Rosetta Genomics' stock going? Where will Rosetta Genomics' stock price be in 2017?
1 equities research analysts have issued twelve-month price objectives for Rosetta Genomics' stock. Their predictions range from $3.50 to $3.50. On average, they anticipate Rosetta Genomics' share price to reach $3.50 in the next year. View Analyst Ratings for Rosetta Genomics.
Who are some of Rosetta Genomics' key competitors?
Some companies that are related to Rosetta Genomics include Akers Biosciences (AKR), OncoGenex Pharmaceuticals (ACHV), Roka Bioscience (ROKA), Anacor Pharmaceuticals (ANAC), ANI Pharmaceuticals (BPAX), Celator Pharmaceuticals (CPXX), Cellular Dynamics International (ICEL), Covance (CVD), Cyprotex plc (CRX), GenVec (GNVC), ImmunoCellular Therapeutics Ltd (IMUC), Mesoblast limited (MBLTY), Pharmacyclics (PCYC), Prosensa Holding NV (RNA) and Synageva Biopharma Corp (GEVA).
Who are Rosetta Genomics' key executives?
Rosetta Genomics' management team includes the folowing people:
- Brian A. Markison, Chairman of the Board
- Kenneth A. Berlin, President, Chief Executive Officer
- Ron Kalfus, Chief Financial Officer
- Douglas Sites, Executive Vice President - Sales and Marketing
- Dganit Bar Ph.D., Chief Scientific Officer
- Eti Meiri Ph.D., Vice President - Research
- Oded Biran, General Counsel
- E. Robert Wassman M.D., Chief Medical Officer
- Kevin Watson, Director, Reimbursement-Managed Care
- Roy N. Davis, Director
How do I buy Rosetta Genomics stock?
Shares of Rosetta Genomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rosetta Genomics' stock price today?
MarketBeat Community Rating for Rosetta Genomics (NASDAQ ROSG)MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Rosetta Genomics stock can currently be purchased for approximately $1.36.
Earnings History for Rosetta Genomics (NASDAQ:ROSG)Earnings History by Quarter for Rosetta Genomics (NASDAQ ROSG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/26/2016||Q216||($0.17)||($0.16)||$2.89 million||$2.41 million||View||Listen|
|5/19/2016||Q116||($0.16)||($0.18)||$3.36 million||$2.60 million||View||Listen|
|3/23/2016||Q415||($0.33)||($0.14)||$3.50 million||$3.60 million||View||Listen|
Earnings Estimates for Rosetta Genomics (NASDAQ:ROSG)
Current Year EPS Consensus Estimate: $-5.64 EPS
Next Year EPS Consensus Estimate: $-3.96 EPS
Dividend History for Rosetta Genomics (NASDAQ:ROSG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Rosetta Genomics (NASDAQ:ROSG)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Rosetta Genomics (NASDAQ:ROSG)
Latest Headlines for Rosetta Genomics (NASDAQ:ROSG)
Rosetta Genomics (ROSG) Chart for Monday, September, 25, 2017